Methodological arguments for the necessity of randomized trials in high-dose chemotherapy for breast cancer

By Schmoor C.   Schumacher M.  

Breast Cancer Research and Treatment, Vol. 54, Iss. 1, 1999-03 ,pp. : 31-38

Springer Publishing Company

Access to resources Recommend Favorite

Paclitaxel-containing High-dose Chemotherapy in High-risk Breast Cancer Patients

By Greinix Hildegard T.   Linkesch Werner   Seifert Manfred   Kubista Ernst   Czerwenka Klaus   Elahi Fariborz   Zielinski Christoph   Hoecker Paul   Steger Günther   Schulenburg Axel   Neumeister Geralt   Rabitsch Werner   Jakesz Raimund   Kalhs Peter  

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

High-dose Chemotherapy of Breast Cancer: Current Status and Developmental Strategies

By Crown J.   Raptis G.   Hamilton N.   Fennelly D.   Vahdat L.   Norton L.  

European Journal of Cancer, Vol. 31, Iss. 5, 1995-01 ,pp. : 809-811

Elsevier

Access to resources Recommend Favorite

High-dose Chemotherapy in Tumours Other Than Lymphomas and Breast Cancer

By Droz J.P.   Biron P.  

European Journal of Cancer, Vol. 31, Iss. 5, 1995-01 ,pp. : 811-812

Elsevier

Access to resources Recommend Favorite

Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

By Espinosa E.   Morales S.   Borrega P.   Casas A.   Madroñal C.   Machengs I.   Illarramendi J.   Lizón J.   Moreno J.   Belón J.   Janáriz J.   Puente M.   Checa T.   Mel J.   González Barón M.  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 6, 2004-12 ,pp. : 546-552

Springer Publishing Company

Access to resources Recommend Favorite